Barclays’s Nephros NEPH Stock Holding History

Barclays’s Portfolio NEPH Stock Details NEPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-106	Closed	-$501	–	5536
2025 Q3	$501	Buy	+106	New	+$416	﹤0.01%	5205

Other funds holding NEPH

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Barclays's NEPH Position: Q4 2025 in Review

Barclays sold out of Nephros (NEPH) in Q4 2025, closing a stake of 106 shares — an estimated $501 sold.

Barclays first reported a position in NEPH in Q3 2025 and held it in 1 quarter. The position peaked at $501 in Q3 2025. 35 funds tracked by Wall St. Rank hold NEPH as of Q4 2025.

Barclays reported no remaining Nephros position as of Q4 2025 after selling out during the quarter.
Barclays sold 106 Nephros shares in Q4 2025, an estimated $501.
Barclays first reported a position in Nephros in Q3 2025 and held it in 1 quarter.
Barclays's Nephros position peaked at $501 in Q3 2025.
35 funds tracked by Wall St. Rank held Nephros as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.